According to filings with the U.S. Securities and Exchange Commission, Avicenna Biosciences is raising up to $6,000,000.00 in new funding. Sources indicate that as part of senior management President, Christopher Meldrum played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Avicenna Biosciences
Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks. We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful transforming sub-optimal development candidates into life-saving drugs. The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

To learn more about Avicenna Biosciences, visit http://www.avicenna-bio.com/
Avicenna Biosciences Linkedin Page: https://www.linkedin.com/company/avicenna-biosciences/

Contact:
Christopher Meldrum, President
919-667-2504
https://www.linkedin.com/in/chrismeldrum/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.